|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MYB |
Gene summary for MYB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MYB | Gene ID | 4602 |
| Gene name | MYB proto-oncogene, transcription factor | |
| Gene Alias | Cmyb | |
| Cytomap | 6q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P10242 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4602 | MYB | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.28e-12 | -4.18e-01 | 0.0155 |
| 4602 | MYB | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.82e-04 | -4.60e-01 | -0.1808 |
| 4602 | MYB | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.87e-05 | -5.25e-01 | -0.1207 |
| 4602 | MYB | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.52e-03 | -3.00e-01 | 0.0674 |
| 4602 | MYB | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.87e-27 | -6.64e-01 | 0.3005 |
| 4602 | MYB | F007 | Human | Colorectum | FAP | 3.46e-04 | -3.43e-01 | 0.1176 |
| 4602 | MYB | A001-C-207 | Human | Colorectum | FAP | 3.60e-05 | -3.00e-01 | 0.1278 |
| 4602 | MYB | A015-C-203 | Human | Colorectum | FAP | 3.78e-28 | -3.53e-01 | -0.1294 |
| 4602 | MYB | A015-C-204 | Human | Colorectum | FAP | 3.61e-06 | -3.38e-01 | -0.0228 |
| 4602 | MYB | A014-C-040 | Human | Colorectum | FAP | 1.96e-03 | -3.15e-01 | -0.1184 |
| 4602 | MYB | A002-C-201 | Human | Colorectum | FAP | 1.45e-13 | -3.14e-01 | 0.0324 |
| 4602 | MYB | A002-C-203 | Human | Colorectum | FAP | 3.70e-07 | -2.86e-01 | 0.2786 |
| 4602 | MYB | A001-C-119 | Human | Colorectum | FAP | 1.38e-06 | -3.48e-01 | -0.1557 |
| 4602 | MYB | A001-C-108 | Human | Colorectum | FAP | 1.36e-17 | -3.39e-01 | -0.0272 |
| 4602 | MYB | A002-C-205 | Human | Colorectum | FAP | 4.88e-20 | -3.57e-01 | -0.1236 |
| 4602 | MYB | A001-C-104 | Human | Colorectum | FAP | 2.71e-08 | -2.79e-01 | 0.0184 |
| 4602 | MYB | A015-C-005 | Human | Colorectum | FAP | 9.20e-03 | -1.67e-01 | -0.0336 |
| 4602 | MYB | A015-C-006 | Human | Colorectum | FAP | 2.37e-16 | -4.75e-01 | -0.0994 |
| 4602 | MYB | A015-C-106 | Human | Colorectum | FAP | 4.39e-10 | -1.41e-01 | -0.0511 |
| 4602 | MYB | A002-C-114 | Human | Colorectum | FAP | 2.27e-17 | -3.41e-01 | -0.1561 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006979 | Colorectum | AD | response to oxidative stress | 145/3918 | 446/18723 | 5.16e-09 | 3.23e-07 | 145 |
| GO:0062197 | Colorectum | AD | cellular response to chemical stress | 109/3918 | 337/18723 | 5.33e-07 | 1.95e-05 | 109 |
| GO:0000302 | Colorectum | AD | response to reactive oxygen species | 78/3918 | 222/18723 | 6.17e-07 | 2.21e-05 | 78 |
| GO:0070997 | Colorectum | AD | neuron death | 114/3918 | 361/18723 | 1.13e-06 | 3.72e-05 | 114 |
| GO:0034599 | Colorectum | AD | cellular response to oxidative stress | 94/3918 | 288/18723 | 2.03e-06 | 6.02e-05 | 94 |
| GO:1901214 | Colorectum | AD | regulation of neuron death | 99/3918 | 319/18723 | 1.26e-05 | 2.76e-04 | 99 |
| GO:0042542 | Colorectum | AD | response to hydrogen peroxide | 52/3918 | 146/18723 | 2.83e-05 | 5.30e-04 | 52 |
| GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
| GO:0051402 | Colorectum | AD | neuron apoptotic process | 77/3918 | 246/18723 | 8.07e-05 | 1.28e-03 | 77 |
| GO:0045785 | Colorectum | AD | positive regulation of cell adhesion | 122/3918 | 437/18723 | 2.65e-04 | 3.28e-03 | 122 |
| GO:0051047 | Colorectum | AD | positive regulation of secretion | 90/3918 | 310/18723 | 4.11e-04 | 4.66e-03 | 90 |
| GO:0010720 | Colorectum | AD | positive regulation of cell development | 87/3918 | 298/18723 | 4.17e-04 | 4.71e-03 | 87 |
| GO:0070482 | Colorectum | AD | response to oxygen levels | 99/3918 | 347/18723 | 4.29e-04 | 4.82e-03 | 99 |
| GO:0034614 | Colorectum | AD | cellular response to reactive oxygen species | 50/3918 | 155/18723 | 6.25e-04 | 6.49e-03 | 50 |
| GO:1903532 | Colorectum | AD | positive regulation of secretion by cell | 82/3918 | 282/18723 | 6.85e-04 | 7.00e-03 | 82 |
| GO:0043523 | Colorectum | AD | regulation of neuron apoptotic process | 64/3918 | 212/18723 | 8.95e-04 | 8.63e-03 | 64 |
| GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
| GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
| GO:0001666 | Colorectum | AD | response to hypoxia | 86/3918 | 307/18723 | 1.77e-03 | 1.46e-02 | 86 |
| GO:0050767 | Colorectum | AD | regulation of neurogenesis | 99/3918 | 364/18723 | 2.35e-03 | 1.82e-02 | 99 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04151 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa041511 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa041512 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
| hsa041513 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
| hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| MYB | STM | Breast | Healthy | ANKRD30A,ESR1,SGK3, etc. | 1.11e-01 |  |
| MYB | MAST | Breast | IDC | NUCB2,SLC39A6,VWA5A, etc. | 5.30e-02 |  |
| MYB | CT | Colorectum | FAP | LRGUK,XACT,NINL, etc. | 4.62e-03 |  |
| MYB | SSC | Colorectum | FAP | LRGUK,XACT,NINL, etc. | 3.38e-04 | |
| MYB | ASC | Colorectum | SER | NREP,APCDD1,FOXA1, etc. | 1.08e-01 |  |
| MYB | MAST | Colorectum | AD | MAOA,ZNF704,PAM, etc. | 2.48e-01 |  |
| MYB | TREG | Colorectum | ADJ | MAOA,ZNF704,PAM, etc. | 1.29e-01 |  |
| MYB | MAST | Colorectum | ADJ | MAOA,ZNF704,PAM, etc. | 9.16e-02 | |
| MYB | TREG | Colorectum | FAP | MAOA,ZNF704,PAM, etc. | 1.08e-01 | |
| MYB | MAST | Colorectum | MSI-H | MAOA,ZNF704,PAM, etc. | 6.24e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MYB | SNV | Missense_Mutation | c.308N>C | p.Val103Ala | p.V103A | P10242 | protein_coding | deleterious(0.02) | probably_damaging(0.965) | TCGA-A2-A1FZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Arimidex | SD | |
| MYB | SNV | Missense_Mutation | c.916N>A | p.Glu306Lys | p.E306K | P10242 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| MYB | SNV | Missense_Mutation | c.1575C>G | p.Asn525Lys | p.N525K | P10242 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MYB | SNV | Missense_Mutation | c.403C>T | p.His135Tyr | p.H135Y | P10242 | protein_coding | deleterious(0) | benign(0.019) | TCGA-C8-A133-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| MYB | SNV | Missense_Mutation | c.1570T>G | p.Leu524Val | p.L524V | P10242 | protein_coding | tolerated(0.05) | probably_damaging(0.995) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD | |
| MYB | insertion | Frame_Shift_Ins | novel | c.281_282insT | p.Trp95LeufsTer37 | p.W95Lfs*37 | P10242 | protein_coding | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | ||
| MYB | deletion | Frame_Shift_Del | novel | c.1946_1947delNN | p.Gln649ArgfsTer7 | p.Q649Rfs*7 | P10242 | protein_coding | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| MYB | insertion | Frame_Shift_Ins | novel | c.1243_1244insCAACCTCTAGCACTATTAAAAACAGGGTCTTGCA | p.Phe415SerfsTer13 | p.F415Sfs*13 | P10242 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| MYB | deletion | Frame_Shift_Del | c.1710delN | p.Phe571LeufsTer11 | p.F571Lfs*11 | P10242 | protein_coding | TCGA-BH-A0E7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |||
| MYB | insertion | Frame_Shift_Ins | novel | c.418_419insCA | p.Glu141GlnfsTer81 | p.E141Qfs*81 | P10242 | protein_coding | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4602 | MYB | CLINICALLY ACTIONABLE | RETINOID | 8670250 | ||
| 4602 | MYB | CLINICALLY ACTIONABLE | 12-O-TETRADECANOYLPHORBOL-13-ACETATE | 12354938 | ||
| 4602 | MYB | CLINICALLY ACTIONABLE | 5-FLUOROURACIL | FLUOROURACIL | 15001837 | |
| 4602 | MYB | CLINICALLY ACTIONABLE | DOXORUBICIN | DOXORUBICIN | 15001837 | |
| 4602 | MYB | CLINICALLY ACTIONABLE | G4460 | |||
| 4602 | MYB | CLINICALLY ACTIONABLE | TAXOL | PACLITAXEL | 15001837 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |